Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
19 mars 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
12 mars 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
08 mars 2024 08h50 HE
|
Acumen Pharmaceuticals, Inc.
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop...
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
21 févr. 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind...
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
01 févr. 2024 07h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 janv. 2024 16h15 HE
|
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals to present at the JPMorgan Healthcare Conference.
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
13 nov. 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 ...
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
13 nov. 2023 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 ...
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
07 nov. 2023 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
06 nov. 2023 16h01 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company...